<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36481799</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Prospects for gene replacement therapies in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>52</EndPage><MedlinePgn>39-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-022-00751-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating and incurable neurodegenerative disease characterized by the progressive loss of upper and lower motor neurons. ALS causes death, usually within 2-5 years of diagnosis. Riluzole, the only drug currently approved in Europe for the treatment of this condition, offers only a modest benefit, increasing survival by 3 months on average. Recent advances in our understanding of causative or disease-modifying genetic variants and in the development of genetic therapy strategies present exciting new therapeutic opportunities for ALS. In addition, the approval of adeno-associated virus-mediated delivery of functional copies of the SMN1 gene to treat spinal muscular atrophy represents an important therapeutic milestone and demonstrates the potential of gene replacement therapies for motor neuron disorders. In this Review, we describe the current landscape of genetic therapies in ALS, highlighting achievements and critical challenges. In particular, we discuss opportunities for gene replacement therapy in subgroups of people with ALS, and we describe loss-of-function mutations that are known to contribute to the pathophysiology of ALS and could represent novel targets for gene replacement therapies.</AbstractText><CopyrightInformation>&#xa9; 2022. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giovannelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higginbottom</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7468-5917</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzouz</LastName><ForeName>Mimoun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK. pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36481799</ArticleId><ArticleId IdType="doi">10.1038/s41582-022-00751-5</ArticleId><ArticleId IdType="pii">10.1038/s41582-022-00751-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme, P., Robberecht, W. &amp; Van Den Bosch, L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech. 10, 537&#x2013;549 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.029058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagoshi, N., Nakashima, H. &amp; Fehlings, M. G. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules 20, 7775&#x2013;7789 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules20057775</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, T. et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17, 416&#x2013;422 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505&#x2013;512 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>King, A. E., Woodhouse, A., Kirkcaldie, M. T. &amp; Vickers, J. C. Excitotoxicity in ALS: overstimulation, or overreaction? Exp. Neurol. 275, 162&#x2013;171 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson, B. C., Shaw, P. J., Azzouz, M., Highley, J. R. &amp; Hautbergue, G. M. Proteinopathies as hallmarks of impaired gene expression, proteostasis and mitochondrial function in amyotrophic lateral sclerosis. Front. Neurosci. 15, 783624 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.783624</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, E. F., Shaw, P. J. &amp; De Vos, K. J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 710, 132933 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber, S. C. &amp; Shaw, P. J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free. Radic. Biol. Med. 48, 629&#x2013;641 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. &amp; Wang, F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front. Immunol. 8, 1005 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti, Z. &amp; Patten, S. A. RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 9, 712 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi, A. et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 15, 1182&#x2013;1194 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen, P. M. &amp; Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 7, 603&#x2013;615 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini, R. et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front. Neurosci. 13, 1310 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan, R. et al. Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front. Neurosci. 14, 684 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00684</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, H., Gao, K. &amp; Jankovic, J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10, 337&#x2013;348 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713&#x2013;1722 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy, S. et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr. Pulmonol. 54, 179&#x2013;185 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.24203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy, S. M. Onasemnogene abeparvovec: first global approval. Drugs 79, 1255&#x2013;1262 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01162-5</ArticleId></ArticleIdList></Reference><Reference><Citation>High, K. A. &amp; Roncarolo, M. G. Gene therapy. N. Engl. J. Med. 381, 455&#x2013;464 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1706910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, R. &amp; Xu, Z. Gene therapy: a double-edged sword with great powers. Mol. Cell Biochem. 474, 73&#x2013;81 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-03834-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado, D. A. &amp; Davidson, B. L. Gene therapy for ALS: a review. Mol. Ther. 29, 3345&#x2013;3358 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams, D., Koike, H., Slama, M. &amp; Coelho, T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat. Rev. Neurol. 15, 387&#x2013;404 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0210-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam, S. J. Inotersen: first global approval. Drugs 78, 1371&#x2013;1376 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-018-0968-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri, E., Pera, M. C., Scoto, M., Finkel, R. &amp; Muntoni, F. Spinal muscular atrophy &#x2013; insights and challenges in the treatment era. Nat. Rev. Neurol. 16, 706&#x2013;715 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00413-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Q. Nusinersen as a therapeutic agent for spinal muscular atrophy. Yonsei Med. J. 61, 273&#x2013;283 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2020.61.4.273</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonka, S., Hennlein, L. &amp; Sendtner, M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol. Res. Pract. 4, 2 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-021-00162-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin, F., Rudin, C. M. &amp; Sen, T. CRISPR gene therapy: applications, limitations, and implications for the future. Front. Oncol. 10, 1387 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.01387</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493&#x2013;502 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107454</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner, D., Ludolph, A. C. &amp; Weishaupt, J. H. Gene specific therapies &#x2013; the next therapeutic milestone in neurology. Neurol. Res. Pract. 2, 25 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-020-00075-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Y. C. &amp; Guo, Y. L. Less is more, natural loss-of-function mutation is a strategy for adaptation. Plant. Commun. 1, 100103 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xplc.2020.100103</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. &amp; Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 767 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S. &amp; Simonato, M. Gene therapy tools for brain diseases. Front. Pharmacol. 10, 724 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00724</ArticleId></ArticleIdList></Reference><Reference><Citation>Naso, M. F., Tomkowicz, B., Perry, W. L. &amp; Strohl, W. R. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31, 317&#x2013;334 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-017-0234-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A. &amp; Gray, S. J. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J. Neurodev. Disord. 10, 16 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11689-018-9234-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cearley, C. N. &amp; Wolfe, J. H. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13, 528&#x2013;537 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2005.11.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59&#x2013;65 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, S. J. et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058&#x2013;1069 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.72</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry, E. &amp; Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839&#x2013;862 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessler, D. J., Tai, P. W. L., Li, J. &amp; Gao, G. Intravenous infusion of AAV for widespread gene delivery to the nervous system. Methods Mol. Biol. 1950, 143&#x2013;163 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9139-6_8</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella, P., Ronzitti, G. &amp; Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87&#x2013;104 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Domenger, C. &amp; Grimm, D. Next-generation AAV vectors &#x2013; do not judge a virus (only) by its cover. Hum. Mol. Genet. 28, R3&#x2013;R14 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz148</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell, S. K., Rivera-Soto, R. &amp; Gray, S. J. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov. Med. 19, 49&#x2013;57 (2015).</Citation></Reference><Reference><Citation>Gray, S. J. et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143&#x2013;1153 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2010.245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, H. et al. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911&#x2013;917 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2003.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Inagaki, K. et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45&#x2013;53 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2006.03.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, R. et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8, 1323&#x2013;1332 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3301529</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieuwenhuis, B. et al. Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters. Gene Ther. 28, 56&#x2013;74 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-0169-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashchuk, V., Lewis, K. E., Coldicott, I., Grierson, A. J. &amp; Azzouz, M. AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice. Mol. Ther. Methods Clin. Dev. 3, 15055 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2015.55</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204&#x2013;209 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson, K. L., Dayton, R. D., Deverman, B. E. &amp; Klein, R. L. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front. Mol. Neurosci. 9, 116 (2016).</Citation></Reference><Reference><Citation>McCarty, D. M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16, 1648&#x2013;1656 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.171</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty, D. M., Monahan, P. E. &amp; Samulski, R. J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248&#x2013;1254 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3301514</ArticleId></ArticleIdList></Reference><Reference><Citation>High-dose AAV gene therapy deaths. Nat. Biotechnol. 38, 910 (2020).</Citation></Reference><Reference><Citation>Philippidis, A. Fourth boy dies in clinical trial of Astellas&#x2019; AT132. Hum. Gene Ther. 32, 1008&#x2013;1010 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2021.29182.bfs</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704&#x2013;712 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2009.182</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J. &amp; Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199, 381&#x2013;390 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/595830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruzik, A. et al. Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol. Ther. Methods Clin. Dev. 14, 126&#x2013;133 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2019.05.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber, T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front. Immunol. 12, 658399 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658399</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcedo, R. et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccin. Immunol. 18, 1586&#x2013;1588 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05107-11</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog, R. W. Complexity of immune responses to AAV transgene products &#x2013; example of factor IX. Cell Immunol. 342, 103658 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2017.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mingozzi, F. &amp; High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23&#x2013;36 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-01-306647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury, E. A. et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. Adv. Drug. Deliv. Rev. 170, 214&#x2013;237 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.01.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincents, B., von Pawel-Rammingen, U., Bjorck, L. &amp; Abrahamson, M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43, 15540&#x2013;15549 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi048284d</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M. &amp; Asokan, A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight 5, e139881 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139881</ArticleId></ArticleIdList></Reference><Reference><Citation>Leborgne, C. et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat. Med. 26, 1096&#x2013;1101 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0911-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros-Ga&#xf1;&#xe1;n, I. et al. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies. Clin. Transl. Immunol. 11, e1375 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1375</ArticleId></ArticleIdList></Reference><Reference><Citation>Srejovic, I. et al. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 10, 798 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10050798</ArticleId></ArticleIdList></Reference><Reference><Citation>Denard, J. et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86, 6620&#x2013;6631 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-12</ArticleId></ArticleIdList></Reference><Reference><Citation>Denard, J. et al. AAV-8 and AAV-9 vectors cooperate with serum proteins differently than AAV-1 and AAV-6. Mol. Ther. Methods Clin. Dev. 10, 291&#x2013;302 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2018.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella, M., Ciotti, C., Cohen-Tannoudji, M. &amp; Biferi, M. G. Gene therapy for ALS &#x2013; a perspective. Int. J. Mol. Sci. 20, 4388 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarrott, J. M., Herranz-Mart&#xed;n, S., Alrafiah, A. R., Shaw, P. J. &amp; Azzouz, M. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert. Opin. Biol. Ther. 15, 935&#x2013;947 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2015.1044894</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558&#x2013;3567 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, T. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099&#x2013;1110 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, C. Tailored treatment for ALS poised to move ahead. Nat. Med. https://doi.org/10.1038/d41591-019-00013-w (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-019-00013-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen. Biogen and Ionis announce topline phase 1 study results of investigational drug in C9orf72 amyotrophic lateral sclerosis. Biogen https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results (2022).</Citation></Reference><Reference><Citation>Pena, S. A. et al. Gene therapy for neurological disorders: challenges and recent advancements. J. Drug. Target. 28, 111&#x2013;128 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186X.2019.1630415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tora, M. S., Keifer, O. P., Lamanna, J. J. &amp; Boulis, N. M. The challenges of developing a gene therapy for amyotrophic lateral sclerosis. Expert. Rev. Neurother. 17, 323&#x2013;325 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2017.1287565</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, X. et al. Divergence, convergence, and therapeutic implications: a cell biology perspective of C9ORF72-ALS/FTD. Mol. Neurodegener. 15, 34 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00383-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue, G. M., Cleary, J. D., Guo, S. &amp; Ranum, L. P. W. Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 34, 748&#x2013;755 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. B., Lee, V. M. &amp; Trojanowski, J. Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38&#x2013;50 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3121</ArticleId></ArticleIdList></Reference><Reference><Citation>An, H. et al. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 7, 7 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0658-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp, K. &amp; Barmada, S. J. TDP43 and RNA instability in amyotrophic lateral sclerosis. Brain Res. 1693, 67&#x2013;74 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.01.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood, A., Gurfinkel, Y., Polain, N., Lamont, W. &amp; Lyn Rea, S. Molecular mechanisms underlying TDP-43 pathology in cellular and animal models of ALS and FTLD. Int. J. Mol. Sci. 22, 4705 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094705</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkler, C., Barhum, Y., Ben-Zur, T. &amp; Offen, D. Multifactorial gene therapy enhancing the glutamate uptake system and reducing oxidative stress delays symptom onset and prolongs survival in the SOD1-G93A ALS mouse model. J. Mol. Neurosci. 58, 46&#x2013;58 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-015-0695-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum, L. T. &amp; Trotti, D. EAAT2 and the molecular signature of amyotrophic lateral sclerosis. Adv. Neurobiol. 16, 117&#x2013;136 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-55769-4_6</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal, N. A. et al. Addressing heterogeneity in amyotrophic lateral sclerosis clinical trials. Muscle Nerve 62, 156&#x2013;166 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti, C. et al. Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 21, 485&#x2013;495 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Q., Jiao, B. &amp; Shen, L. The development of C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia disorders. Front. Genet. 11, 562758 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.562758</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers, J., Banchi, E. G. &amp; Latouche, M. C9ORF72: what it is, what it does, and why it matters. Front. Cell Neurosci. 15, 661447 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A. &amp; Patel, B. K. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 12, 25 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk, T. R. &amp; Rousseaux, M. W. C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 15, 45 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli, E. T. et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436&#x2013;1441 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, R., Zhang, Q. &amp; Xu, P. TBK1, a central kinase in innate immune sensing of nucleic acids and beyond. Acta Biochim. Biophys. Sin. 52, 757&#x2013;767 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmaa051</ArticleId></ArticleIdList></Reference><Reference><Citation>Herhaus, L. TBK1 (TANK-binding kinase 1)-mediated regulation of autophagy in health and disease. Matrix Biol. 100&#x2013;101, 84&#x2013;98 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2021.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry, A. K., Chow, E. K., Goodnough, J. B., Yeh, W. C. &amp; Cheng, G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J. Exp. Med. 199, 1651&#x2013;1658 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20040528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett. 587, 542&#x2013;548 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyahira, A. K., Shahangian, A., Hwang, S., Sun, R. &amp; Cheng, G. TANK-binding kinase-1 plays an important role during in vitro and in vivo type I IFN responses to DNA virus infections. J. Immunol. 182, 2248&#x2013;2257 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0802466</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes, J. A., Davies, M. C. &amp; Collins, M. O. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain 10, 5 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomerantz, J. L. &amp; Baltimore, D. NF-&#x3ba;B activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 18, 6694&#x2013;6704 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.23.6694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, J. et al. The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-&#x3ba;B signaling. Nat. Immunol. 13, 1101&#x2013;1109 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, P. et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell 172, 731&#x2013;743.e12 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo, J. M., Ordureau, A., Paulo, J. A., Rinehart, J. &amp; Harper, J. W. The PINK1-PARKIN mitochondrial ubiquitylation pathway drives a program of OPTN/NDP52 recruitment and TBK1 activation to promote mitophagy. Mol. Cell 60, 7&#x2013;20 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicencio, E. et al. Implications of selective autophagy dysfunction for ALS pathology. Cells 9, 381 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai, P. C. et al. Mutational analysis of TBK1 in Taiwanese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 40, 191.e11&#x2013;191.e16 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.12.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, K. L. et al. Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. Neurobiol. Aging 36, 3334.e1&#x2013;3334.e5 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu, S. et al. Screening of the TBK1 gene in familial and sporadic amyotrophic lateral sclerosis patients of Chinese origin. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 605&#x2013;607 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi, L. et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterisation. J. Neurol. Neurosurg. Psychiatry 88, 869&#x2013;875 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316174</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo, M. et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging 71, 266.e1&#x2013;266.e10 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich, M. et al. Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 46, 279&#x2013;291 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, J. et al. Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity. Proc. Natl Acad. Sci. USA 116, 24517&#x2013;24526 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1915732116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck, I. et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 85, 2116&#x2013;2125 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier, C. et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77&#x2013;92 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee, J. et al. TBK1 mutation spectrum in an extended European patient cohort with frontotemporal dementia and amyotrophic lateral sclerosis. Hum. Mutat. 38, 297&#x2013;309 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23161</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster, A. D. et al. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Mol. Cell Neurosci. 108, 103539 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2020.103539</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding, O. et al. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy. Proc. Natl Acad. Sci. USA 118, e2025053118 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025053118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnard, M. et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-&#x3ba;B-dependent gene transcription. EMBO J. 19, 4976&#x2013;4985 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.18.4976</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner, D. et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 216, 267&#x2013;278 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180729</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino, V. et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 106, 789&#x2013;805.e5 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno, C. et al. Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Commun. 2, fcaa133 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa133</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, W. et al. Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice. Aging 11, 2457&#x2013;2476 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying, H. &amp; Yue, B. Y. Optineurin: the autophagy connection. Exp. Eye Res. 144, 73&#x2013;80 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2015.06.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal, M., Swarup, G. &amp; Balasubramanian, D. Functional analysis of optineurin and some of its disease-associated mutants. IUBMB Life 67, 120&#x2013;128 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.1355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sippl, C., Zeilbeck, L. F., Fuchshofer, R. &amp; Tamm, E. R. Optineurin associates with the podocyte Golgi complex to maintain its structure. Cell Tissue Res. 358, 567&#x2013;583 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-014-1968-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahlender, D. A. et al. Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. J. Cell Biol. 169, 285&#x2013;295 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200501162</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, B. C., Shen, X., Samaraweera, M. &amp; Yue, B. Y. Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types. Am. J. Pathol. 169, 1976&#x2013;1989 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fifita, J. A. et al. A novel amyotrophic lateral sclerosis mutation in OPTN induces ER stress and Golgi fragmentation in vitro. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 126&#x2013;133 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1218517</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, S. M. et al. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia. Ann. Clin. Transl. Neurol. 6, 2377&#x2013;2383 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50928</ArticleId></ArticleIdList></Reference><Reference><Citation>Korac, J. et al. Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J. Cell Sci. 126, 580&#x2013;592 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.114926</ArticleId></ArticleIdList></Reference><Reference><Citation>McCall, A. L. et al. Respiratory pathology in the Optn<sup>&#x2212;/&#x2212;</sup> mouse model of amyotrophic lateral sclerosis. Respir. Physiol. Neurobiol. 282, 103525 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2020.103525</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223&#x2013;226 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;mer, Z. et al. Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS. Neurobiol. Aging 33, 208.e1&#x2013;208.e5 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein, O. et al. OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. Neurology 86, 446&#x2013;453 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotkine, M. et al. A recessive S174X mutation in optineurin causes amyotrophic lateral sclerosis through a loss of function via allele-specific nonsense-mediated decay. Neurobiol. Aging 106, 1&#x2013;6 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan, S. M. K., Gendron, T. F., Petrucelli, L., Hegele, R. A. &amp; Strong, M. J. OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 75&#x2013;85 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32606</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps, S. et al. Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol. Aging 32, 557.e11&#x2013;557.e13 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada, M. et al. Clinicopathologic features of autosomal recessive amyotrophic lateral sclerosis associated with optineurin mutation. Neuropathology 34, 64&#x2013;70 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, W. C., Li, H. Y., Chen, G. C., Chern, Y. &amp; Tu, P. H. Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism. Autophagy 11, 685&#x2013;700 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.36098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaramoorthy, V. et al. Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis. Hum. Mol. Genet. 24, 3830&#x2013;3846 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv126</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, C. S. &amp; Holzbaur, E. L. Degradation of engulfed mitochondria is rate-limiting in optineurin-mediated mitophagy in neurons. Elife 9, e50260 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.50260</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, A. S. &amp; Holzbaur, E. L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl Acad. Sci. USA 113, E3349&#x2013;E3358 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523810113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa, S. et al. Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis. Nat. Commun. 7, 12547 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12547</ArticleId></ArticleIdList></Reference><Reference><Citation>Akizuki, M. et al. Optineurin suppression causes neuronal cell death via NF-&#x3ba;B pathway. J. Neurochem. 126, 699&#x2013;704 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12326</ArticleId></ArticleIdList></Reference><Reference><Citation>Surpili, M. J., Delben, T. M. &amp; Kobarg, J. Identification of proteins that interact with the central coiled-coil region of the human protein kinase NEK1. Biochemistry 42, 15369&#x2013;15376 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi034575v</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo-Hanchuk, T. D. et al. NEK1 kinase domain structure and its dynamic protein interactome after exposure to cisplatin. Sci. Rep. 7, 5445 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05325-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, H. P. et al. NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. Neurobiol. Aging 61, 255.e1&#x2013;255.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry, A. M., O&#x2019;Regan, L., Sabir, S. R. &amp; Bayliss, R. Cell cycle regulation by the NEK family of protein kinases. J. Cell Sci. 125, 4423&#x2013;4433 (2012).</Citation></Reference><Reference><Citation>Chen, Y., Craigen, W. J. &amp; Riley, D. J. Nek1 regulates cell death and mitochondrial membrane permeability through phosphorylation of VDAC1. Cell Cycle 8, 257&#x2013;267 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.8.2.7551</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Gaczynska, M., Osmulski, P., Polci, R. &amp; Riley, D. J. Phosphorylation by Nek1 regulates opening and closing of voltage dependent anion channel 1. Biochem. Biophys. Res. Commun. 394, 798&#x2013;803 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.03.077</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner, D. et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain 139, e28 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante, S. et al. Novel variants and cellular studies on patients&#x2019; primary fibroblasts support a role for NEK1 missense variants in ALS pathogenesis. Hum. Mol. Genet. 30, 65&#x2013;71 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab015</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin, J. et al. NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 30, 150&#x2013;162 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mah, L. J., El-Osta, A. &amp; Karagiannis, T. C. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24, 679&#x2013;686 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2010.6</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson, G. et al. Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P<sub>2</sub> phosphatase FIG4. Brain 134, 1959&#x2013;1971 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr148</ArticleId></ArticleIdList></Reference><Reference><Citation>Marat, A. L. &amp; Haucke, V. Phosphatidylinositol 3-phosphates &#x2013; at the interface between cell signalling and membrane traffic. EMBO J. 35, 561&#x2013;579 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201593564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow, C. Y. et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am. J. Hum. Genet. 84, 85&#x2013;88 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanovic, A. et al. FIG4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study. Eur. J. Hum. Genet. 25, 324&#x2013;331 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2016.186</ArticleId></ArticleIdList></Reference><Reference><Citation>Duex, J. E., Nau, J. J., Kauffman, E. J. &amp; Weisman, L. S. Phosphoinositide 5-phosphatase Fig 4p is required for both acute rise and subsequent fall in stress-induced phosphatidylinositol 3,5-bisphosphate levels. Eukaryot. Cell 5, 723&#x2013;731 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/EC.5.4.723-731.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow, C. Y. et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 448, 68&#x2013;72 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenk, G. M. et al. Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth disease CMT4J. PLoS Genet. 7, e1002104 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharadwaj, R., Cunningham, K. M., Zhang, K. &amp; Lloyd, T. E. FIG4 regulates lysosome membrane homeostasis independent of phosphatase function. Hum. Mol. Genet. 25, 681&#x2013;692 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv505</ArticleId></ArticleIdList></Reference><Reference><Citation>Katona, I. et al. Distinct pathogenic processes between Fig4-deficient motor and sensory neurons. Eur. J. Neurosci. 33, 1401&#x2013;1410 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2011.07651.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X. et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 131, 1990&#x2013;2001 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson, C. J., Lenk, G. M. &amp; Meisler, M. H. Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2. Hum. Mol. Genet. 18, 4868&#x2013;4878 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyotani, A. et al. Knockdown of the Drosophila FIG4 induces deficient locomotive behavior, shortening of motor neuron, axonal targeting aberration, reduction of life span and defects in eye development. Exp. Neurol. 277, 86&#x2013;95 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.12.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Presa, M. et al. AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model. J. Clin. Invest. 131, e137159 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137159</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto, K., Liu, S., Tsuji, T., Olson, K. A. &amp; Hu, G. F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24, 445&#x2013;456 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng, J. &amp; Xu, Z. Three decades of research on angiogenin: a review and perspective. Acta Biochim. Biophys. Sin. 48, 399&#x2013;410 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmv131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. H., Kim, K. W., Min, K. M., Chang, S. I. &amp; Kim, J. C. Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells. Mediat. Inflamm. 2014, 861435 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/861435</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, H. et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 583, 437&#x2013;442 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.12.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki, S., Ivanov, P., Hu, G. F. &amp; Anderson, P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 185, 35&#x2013;42 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200811106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, D. et al. Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann. Neurol. 62, 609&#x2013;617 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21221</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree, B. et al. Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 46, 11810&#x2013;11818 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi701333h</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiyagarajan, N., Ferguson, R., Subramanian, V. &amp; Acharya, K. R. Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat. Commun. 3, 1121 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2126</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi, A. K., Kumar, H., Vasaikar, S. V., Jayaram, B. &amp; Gomes, J. Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. PLoS One 7, e32479 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032479</ArticleId></ArticleIdList></Reference><Reference><Citation>Padhi, A. K., Jayaram, B. &amp; Gomes, J. Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations. Sci. Rep. 3, 1225 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01225</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, V. &amp; Feng, Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 16, 1445&#x2013;1453 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm095</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, V., Crabtree, B. &amp; Acharya, K. R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum. Mol. Genet. 17, 130&#x2013;149 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran, D. et al. Control of motoneuron survival by angiogenin. J. Neurosci. 28, 14056&#x2013;14061 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3399-08.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Skorupa, A. et al. Motoneurons secrete angiogenin to induce RNA cleavage in astroglia. J. Neurosci. 32, 5024&#x2013;5038 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6366-11.2012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang, T. T., Johnson, D. A., Raines, R. T. &amp; Johnson, J. A. Angiogenin activates the astrocytic Nrf2/antioxidant-response element pathway and thereby protects murine neurons from oxidative stress. J. Biol. Chem. 294, 15095&#x2013;15103 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.008491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishikawa, H., Wu, D. &amp; Hu, G. F. Targeting angiogenin in therapy of amyotrophic lateral sclerosis. Expert. Opin. Ther. Targets 12, 1229&#x2013;1242 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.12.10.1229</ArticleId></ArticleIdList></Reference><Reference><Citation>Aluri, K. C., Salisbury, J. P., Prehn, J. H. M. &amp; Agar, J. N. Loss of angiogenin function is related to earlier ALS onset and a paradoxical increase in ALS duration. Sci. Rep. 10, 3715 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-60431-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan, B. &amp; Jayandharan, G. R. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr. Gene Ther. 14, 86&#x2013;100 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566523214666140302193709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag, F., Schmidt, K. &amp; Kleinschmidt, J. A. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl Acad. Sci. USA 107, 10220&#x2013;10225 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1001673107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, Z., Zak, R., Zhang, Y. &amp; Engelhardt, J. F. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79, 364&#x2013;379 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.1.364-379.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, V. W., McCarty, D. M. &amp; Samulski, R. J. Host cell DNA repair pathways in adeno-associated viral genome processing. J. Virol. 80, 10346&#x2013;10356 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00841-06</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. J. et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J. Neurosci. 22, 6920&#x2013;6928 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-16-06920.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero, G. et al. Specific expression of glial-derived neurotrophic factor in muscles as gene therapy strategy for amyotrophic lateral sclerosis. Neurotherapeutics 18, 1113&#x2013;1126 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01025-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh, R. H. et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. Nat. Med. 28, 1813&#x2013;1822 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01956-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar, B. K., Llad&#xf3;, J., Sherkat, N., Rothstein, J. D. &amp; Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839&#x2013;842 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, H. et al. Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1 G93A ALS mouse model via upregulation of D-amino acid oxidase. Mol. Neurobiol. 55, 682&#x2013;695 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0335-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. Systemic administration of scAAV9-IGF1 extends survival in SOD1<sup>G93A</sup> ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. Brain Res. Bull. 139, 203&#x2013;210 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz, M. E. et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve 65, 291&#x2013;302 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf, Y., Abramov, N., Harel, A. &amp; Offen, D. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 3, 21 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2001-1326-3-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou, P. et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 73, 337&#x2013;344 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4321</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner, D. et al. Hot-spot KIF5A mutations cause familial ALS. Brain 141, 688&#x2013;697 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas, A. et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97, 1268&#x2013;1283.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, P. D. et al. Unique function of kinesin Kif5A in localization of mitochondria in axons. J. Neurosci. 34, 14717&#x2013;14732 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2770-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano, J., Chiba, K. &amp; Niwa, S. An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity. Genes. Cell 27, 421&#x2013;435 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12936</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron, D. M. et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 39, 110598 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant, D. C. et al. ALS-linked KIF5A &#x394;Exon27 mutant causes neuronal toxicity through gain-of-function. EMBO Rep. 23, e54234 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202154234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>